Bls Pharmaceuticals Limited (ASX: BLS) — Perfil da empresa, notícias e dados financeiros
Bls Pharmaceuticals Limited is a healthcare business and parent company of the Breathe Life Sciences Group, specializing in life sciences, novel therapeutic goods, contract drug manufacturing, and wholesale distribution.
Bls Pharmaceuticals Limited
Bls Pharmaceuticals Limited is a healthcare business and parent company of the Breathe Life Sciences Group, specializing in life sciences, novel therapeutic goods, contract drug manufacturing, and wholesale distribution. The company operates a TGA GMP-licensed facility in Brisbane, producing final dose form medicines and active pharmaceutical ingredients, including controlled substances such as medicinal cannabis, MDMA, and psilocybin. Through its subsidiary networks and proprietary brands, including Dr Watson, the company supplies prescription medicines, consumer health products, and novel foods to clinical trials, authorized prescribers, pharmacies, and retail markets across Australia, Europe, Japan, the United Kingdom, and the United States.
Resumo
Operações
Produtos e/ou serviços de Bls Pharmaceuticals Limited
- Contract Pharmaceutical Manufacturing: TGA GMP-licensed manufacturing of final dose form medicines and active pharmaceutical ingredients at the Brisbane facility, producing over 3,000,000 medicines per year for more than 200 partner brands globally.
- Wholesale and Distribution Services: Wholesale importing, exporting, and distribution of Schedule 3, 4, and 8 controlled substances and investigational medicines to pharmacies, licensed clinics, and wholesale partners across Australia, Europe, and the United Kingdom.
- Medical Cannabis Products: Manufacturing, wholesale, and international supply of medicinal cannabis active pharmaceutical ingredients and finished dosage form products supplied to authorised prescribers, licensed distributors, and patients via special access pathways worldwide.
- MDMA and Psilocybin Therapeutics: GMP final dose form manufacturing and supply of investigational MDMA and psilocybin medicines produced in Australia for clinical trial sponsors and authorised medical prescribers treating depression and affective mental health disorders.
- Prescription and Consumer Health Products: Development and international distribution of proprietary prescription medicines and over-the-counter consumer health products, offering therapeutic formulations containing cannabidiol, nicotinamide adenine dinucleotide, and dietary functional food-grade mushroom extracts.
- Direct-to-Consumer and Retail Wellness Operations: Retail distribution and direct-to-consumer sales of over-the-counter health items and novel food products, including non-prescription cannabidiol items and wellness dietary supplements, across retail markets in the United Kingdom, Australasia, and the United States.
equipe executiva do Bls Pharmaceuticals Limited
- Samuel WatsonCEO, MD & Executive Director
- Guy Adrian RobertsonCFO & Company Secretary
- Jason HineCOO & Executive Director
- Macdarragh O'NeillHead of Production of GMP & Director of BLS Wholesalers Pty
Comunicados recentes
O que a Bls Pharmaceuticals Limited (BLS) comunicou ao mercado, do mais recente para o mais antigo.
- Ceasing to be a substantial holder
- Becoming a substantial holder
- AGM Date and Director Nominations
- Application for quotation of securities - BLS
Principais indicadores financeiros
Resultados divulgados pela Bls Pharmaceuticals Limited, em AUD.
- Cap. de mercado
- 247,9 mi
- Receita (TTM)
- 73,9 mi
- P/L
- 15.0
- LPA (diluído, TTM)
- 0.1
- Dividend yield
- —
- Margem de lucro
- 20.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 74,2 mi | 15,8 mi | 15,4 mi | |
| 9,3 mi | -1,7 mi | -13,3 mi | |
| 5,2 mi | -2,1 mi | -2 mi | |
| 2,4 mi | -257,6 mil | -236,5 mil |